AI
Friday, May 13, 2016 7:30:30 PM
Dr.Bruce.Freimark(PPHM's Dir./Preclin) speaks 8-31-16 at a CHI I-O Conference, describing how “PS targeting antibodies enhance the anti-tumor activity & survival of checkpoint antibodies in preclin. tumor models”...
Aug29-Sept2: “CHI's 4th Annual Immuno-Oncology Summit”, Boston http://www.immuno-oncologysummit.com
“As our understanding of tumor immunology has advanced, immuno-oncology has made unprecedented progress in improving the outcomes for cancer patients. Still, with the field in its infancy, the full curative potential of IO has yet to be realized. CHI’s 4th Annual Immuno-Oncology Summit has been designed to support a coordinated effort by industry players to bring commercial immunotherapies & immunotherapy combinations through clinical development and into the market.”
CHI = Cambridge Healthtech Institute http://www.chicorporate.com - “the preeminent life science network for leading researchers & business experts from top pharmaceutical, biotech, and academic organizations.”
SUB-CONF(1 of 9; 2day): PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY - “Predictive Preclinical Models for Cancer Immunotherapy”
http://www.immuno-oncologysummit.com/Preclinical-Immuno-Oncology
8-31-16 Session: NOVEL IN VITRO MODELS FOR IMMUNOTHERAPY DISCOVERY
Chairperson: Oliver Ghobrial (AbbVie)
12:15pm Bruce Freimark, PhD, Res.Dir., Preclinical Oncology, Peregrine Pharm.
“Tipping the Balance: Overriding Phosphatidylserine-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
OVERVIEW: Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity and survival of checkpoint antibodies in preclinical tumor models by increasing activated cytotoxic T-cell infiltrates and immune stimulatory mediators.
= = = = = = = =KNOWN UPCOMING:
May26: UTSW-MC Hamon Center Lab Seminar, Dallas http://tinyurl.com/ztsyl2w
...9am: Dr. Xianming Huang(Rolf Brekken Lab), "PS-Targeting Antibody Synergizes with Immune Checkpoint Blockade for Cancer Immunotherapy"
Jun2-4: ICDS 2016: Translational Implications in Cell Death", Cork Ireland http://tinyurl.com/h2gvyld
...Dr. Rolf Brekken (USA, UTSE, PPHM SAB): “Blockade of PS & Immune Activation in Cancer” (Chair: Dr. Raymond Birge/Rutgers – see http://tinyurl.com/j3whbx3 )
Jun3-7(PPHM Booth #13153): ASCO 2016, Chicago http://am.asco.org (Abstracts released 5-18-16 5pm: http://meetinglibrary.asco.org )
Jun6-9/Avid/Booth5562: BIO Intl. Convention, SanFran http://convention.bio.org
Jun16-19: WISTAR's Regulatory Myeloid Suppressor Cells Conf., Philadelphia http://tinyurl.com/hwrogdk
...SPONSORS: GENERAL: Peregrine, Genentech, J&J(Janssen-Onc); SESSION: Juno, Galera, Reata; DAY: Syndax
...Speaker: Dr. Rolf Brekken [PPHM SAB] (Conf.Chair: Dmitry Gabrilovich, The Wistar Institute, PPHM SAB)
Jun19-22 *Delayed till May'17 due to Unfortunate World Events* “ICDS'16 - From Molecules To Diseases”, Istanbul Turkey http://tinyurl.com/h4zjvo4 - ….Rutgers' Dr. Raymond Birge ( http://birgelab.org ) “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer” - see http://tinyurl.com/j3whbx3
~Jul12: FY'16Q4 (y/e 4-30-16) Financials & Conf. Call http://ir.peregrineinc.com/events.cfm
Aug31: CHI's 4th Annual Immuno-Oncology Summit, Boston http://tinyurl.com/j35f5pr
...12:15pm: Dr. Bruce Freimark (Dir.PreClinRES), “Tipping the Balance: Overriding PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
.
Aug29-Sept2: “CHI's 4th Annual Immuno-Oncology Summit”, Boston http://www.immuno-oncologysummit.com
“As our understanding of tumor immunology has advanced, immuno-oncology has made unprecedented progress in improving the outcomes for cancer patients. Still, with the field in its infancy, the full curative potential of IO has yet to be realized. CHI’s 4th Annual Immuno-Oncology Summit has been designed to support a coordinated effort by industry players to bring commercial immunotherapies & immunotherapy combinations through clinical development and into the market.”
CHI = Cambridge Healthtech Institute http://www.chicorporate.com - “the preeminent life science network for leading researchers & business experts from top pharmaceutical, biotech, and academic organizations.”
SUB-CONF(1 of 9; 2day): PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY - “Predictive Preclinical Models for Cancer Immunotherapy”
http://www.immuno-oncologysummit.com/Preclinical-Immuno-Oncology
8-31-16 Session: NOVEL IN VITRO MODELS FOR IMMUNOTHERAPY DISCOVERY
Chairperson: Oliver Ghobrial (AbbVie)
12:15pm Bruce Freimark, PhD, Res.Dir., Preclinical Oncology, Peregrine Pharm.
“Tipping the Balance: Overriding Phosphatidylserine-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
OVERVIEW: Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity and survival of checkpoint antibodies in preclinical tumor models by increasing activated cytotoxic T-cell infiltrates and immune stimulatory mediators.
= = = = = = = =KNOWN UPCOMING:
May26: UTSW-MC Hamon Center Lab Seminar, Dallas http://tinyurl.com/ztsyl2w
...9am: Dr. Xianming Huang(Rolf Brekken Lab), "PS-Targeting Antibody Synergizes with Immune Checkpoint Blockade for Cancer Immunotherapy"
Jun2-4: ICDS 2016: Translational Implications in Cell Death", Cork Ireland http://tinyurl.com/h2gvyld
...Dr. Rolf Brekken (USA, UTSE, PPHM SAB): “Blockade of PS & Immune Activation in Cancer” (Chair: Dr. Raymond Birge/Rutgers – see http://tinyurl.com/j3whbx3 )
Jun3-7(PPHM Booth #13153): ASCO 2016, Chicago http://am.asco.org (Abstracts released 5-18-16 5pm: http://meetinglibrary.asco.org )
Jun6-9/Avid/Booth5562: BIO Intl. Convention, SanFran http://convention.bio.org
Jun16-19: WISTAR's Regulatory Myeloid Suppressor Cells Conf., Philadelphia http://tinyurl.com/hwrogdk
...SPONSORS: GENERAL: Peregrine, Genentech, J&J(Janssen-Onc); SESSION: Juno, Galera, Reata; DAY: Syndax
...Speaker: Dr. Rolf Brekken [PPHM SAB] (Conf.Chair: Dmitry Gabrilovich, The Wistar Institute, PPHM SAB)
Jun19-22 *Delayed till May'17 due to Unfortunate World Events* “ICDS'16 - From Molecules To Diseases”, Istanbul Turkey http://tinyurl.com/h4zjvo4 - ….Rutgers' Dr. Raymond Birge ( http://birgelab.org ) “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer” - see http://tinyurl.com/j3whbx3
~Jul12: FY'16Q4 (y/e 4-30-16) Financials & Conf. Call http://ir.peregrineinc.com/events.cfm
Aug31: CHI's 4th Annual Immuno-Oncology Summit, Boston http://tinyurl.com/j35f5pr
...12:15pm: Dr. Bruce Freimark (Dir.PreClinRES), “Tipping the Balance: Overriding PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
.
